Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 116

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 116
---

Amount) upfront, with the remainder paid upon each Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, as the case may be, until
such amount is paid in full.

We have also agreed to pay
to the Selling Shareholder $35,000 in cash as reimbursement for the reasonable, out-of-pocket expenses incurred by the Selling Shareholder,
including the legal fees and disbursements of the Selling Shareholder’s legal counsel, in connection with its due diligence investigation
of our company and in connection with the preparation, negotiation and execution of the Purchase Agreement.

Conditions Precedent to Commencement

Our right to commence delivering
Purchase Notices under the Purchase Agreement and the Selling Shareholder’s obligation to accept a Fixed Purchase Notice, VWAP Purchase
Notice or Additional VWAP Purchase Notice, are subject to the initial satisfaction, at the Commencement Date, of the conditions precedent
thereto set forth in the Purchase Agreement, which conditions include, among others, the following:

| • | the accuracy in all material respects of our representations and warranties included in the Purchase Agreement; |

| • | us having performed, satisfied and complied in all material respects with all covenants, agreements and                                
 conditions required by the Purchase Agreement and the Registration Rights Agreement to be performed, satisfied or complied with by us; |

| • | the absence of any material misstatement or omission in the registration statement that includes this 
 prospectus;                                                                                           |

| • | this prospectus, in final form, and all reports, schedules, registrations, forms, statements, information                                 
 and other documents required to have been filed by us with the SEC pursuant to the reporting requirements of the Exchange Act having been 
 so filed;                                                                                                                                 |

| • | the Depositary Shares not having been suspended by the SEC, NASDAQ or FINRA and there not having been                        
 imposed any suspension of, or restriction on, accepting additional deposits of common stock by The Depository Trust Company; |

| 58 |

| • | no condition, occurrence, state of facts or event constituting a Material Adverse Effect (as defined in 
 the Purchase Agreement) shall have occurred and be continuing;                                          |

| • | customary compliance with laws and bankruptcy-related conditions; and |

| • | the receipt by the Selling Shareholder of customary legal opinions, as required under the Purchase Agreement. |

Termination of the Purchase Agreement

Unless earlier terminated
as provided in the Purchase Agreement, the Purchase Agreement will terminate automatically on the earliest to occur of:

| • |